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21 Abstract
2 Objectives: The quality and safety of drug therapy in primary care are global concerns. The Pharmacist and 
3 Data driven Quality Improvement in Primary care (P-DQIP) intervention aims to improve prescribing safety 
4 via an informatics tool which facilitates proactive management of drug therapy risks (DTRs) by health-
5 board employed pharmacists with established roles in general practices. Study objectives were (1) to 
6 identify and prioritise factors that could influence P-DQIP implementation from the perspective of practice 
7 pharmacists, and (2) to identify potentially effective, acceptable and feasible strategies to support P-DQIP 
8 implementation.
9 Design: Semi-structured face-to-face interviews using a Theoretical Domains Framework (TDF) informed 
10 topic guide. The framework method was used for data analysis. Identified implementation factors were 
11 prioritised for intervention based on research team consensus. Candidate intervention functions, 
12 behaviour change techniques (BCTs) and policies targeting these were identified from the Behaviour 
13 Change Wheel. The final intervention content and modes of delivery were agreed with local senior 
14 pharmacists.  
15 Setting: General practices from three Health and Social Care Partnerships (HSCPs) in NHS Tayside.
16 Participants: 14 NHS employed practice pharmacists.
17 Results: Identified implementation factors were linked to thirteen theoretical domains (all except 
18 intentions) and six (skill, memory/attention/decision-making, behavioural regulation, reinforcement, 
19 environmental context/resources, social influences) were prioritised. Three intervention functions 
20 (training, enablement, and environmental restructuring) were relevant and were served by two policy 
21 categories (guidelines, communication/marketing) and eight BCTs (Instructions on how to perform a 
22 behaviour, problem solving, action planning, prompt/cues, goal setting, self-monitoring, feedback, 
23 restructuring the social environment). Intervention components encompass an informatics tool, written 
24 educational material, a workshop for pharmacists, promotional activities, and small financial incentives.
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31 Conclusions: This study explored pharmacists’ perceptions of implementation factors which could 
2 influence management of DTRs in general practices to inform implementation of P-DQIP, which will initially 
3 be implemented in one Scottish health board with parallel evaluation of effectiveness and implementation.
4 Keywords: Quality improvement, Behaviour change wheel, Theoretical domains framework, Behaviour 
5 change techniques, Polypharmacy review, Prescribing safety
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41 Strengths and limitations of this study
2  This qualitative study used a theory-driven and structured approach to identify factors that may
3 influence the sustained implementation of medication safety intervention in primary care (P-DQIP).
4  The design of the P-DQIP intervention combined consideration of theoretically underpinned strategies
5 with knowledge of the local implementation context.
6  The applicability of our findings may be limited to settings, in which NHS employed pharmacists have
7 established roles within general practices. 
8  The prioritisation of theoretical domains may be biased by our previous experience of developing
9 successful prescribing safety interventions in primary care.
10  Intervention design that combines theory and experience limits the ability to test their respective
11 contributions in driving behaviour change. 
12
13
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51 Background
2 The quality and safety of medication use in primary care is an increasing concern in the UK and 
3 internationally. Up to 4% of all unplanned hospital admissions are caused by preventable adverse drug 
4 events (ADEs) [1-5]. Older people are particularly at risk of drug related harm, because of their often 
5 increased susceptibility to ADEs and frequent use of polypharmacy, increasing the likelihood of drug 
6 therapy risks (DTRs) including drug-drug and drug-disease interactions [6, 7]. In parallel to population 
7 aging, the prevalence of polypharmacy and DTRs is rising [8] and so are drug related hospital admissions [9] 
8 as well as outpatient and emergency room visits [10].
9
10 A number of recent UK trials have evaluated interventions, in which electronic medical records (EMRs) 
11 were utilised to identify and target patients with DTRs for review. The pharmacist-led information 
12 technology intervention for medication errors (PINCER) employed pharmacists for 12 weeks to identify and 
13 review patients with high-risk prescribing and monitoring from EHRs [11]. In contrast, the data driven 
14 quality improvement in primary care (DQIP) intervention [12] was GP-led and provided education and a 
15 small financial incentive to promote the use of an informatics tool which identifies and facilitates review of 
16 patients with DTRs. Both trials demonstrated significant reductions in targeted DTRs. However, the impact 
17 of the PINCER intervention waned after withdrawal of pharmacist support, while reductions in targeted 
18 DTRs were sustained in the year after the DQIP intervention ceased (because it led to reduced initiation of 
19 high-risk prescribing by GPs) [11, 12]. Additionally, the DQIP trial provided some evidence of reduced 
20 hospital admissions linked to targeted DTRs [12]. 
21
22 In spite of these encouraging findings, both DQIP and PINCER were limited by their relatively narrow scope 
23 (small number of targeted DTRs). Addressing the needs of older people on multiple drugs requires a much 
24 broader scope to encompass a range of indicators. For example, the Scottish government polypharmacy 
25 working group has developed 69 indicators to identify older people with DTRs linked to 18 ADEs (e.g. falls 
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61 and fractures, bleeding, hypoglycaemia) from electronic medical records [13]. Inevitably, a broader scope 
2 will lead to identifying more patients needing review, which has resource implications [14]. In response to 
3 the GP workforce crisis, all four UK countries are currently investing in new posts for pharmacists to work 
4 alongside general practice teams, with NHS England investing £130 million for 2,000 additional practice 
5 pharmacists [15-18]. 
6
7 P-DQIP aims to implement and evaluate a DTR management intervention that is pharmacist and data-
8 driven and deliverable, scalable and sustainable in the UK’s National Health Service. Given prior evidence of 
9 effectiveness, we plan to include in the intervention core elements from PINCER [11] (pharmacist-driven 
10 approach) and DQIP [12] (informatics tool to identify and review patients with DTRs). P-DQIP will target a 
11 broader range of DTRs relevant to older people, and rather than employing new pharmacists (as in 
12 PINCER), NHS-employed pharmacists already affiliated with general practices will work as part of practice 
13 teams in order to facilitate sustained impact. 
14
15 The aim of this study was to systematically develop a theoretically informed strategy to support 
16 implementation of P-DQIP in NHS Scotland. To this end, it is important to understand factors that may 
17 drive successful implementation. For the purposes of this study, we define implementation factors as 
18 characteristics of individuals or the environment they work in, which may influence the implementation of 
19 P-DQIP. The study objectives were (1) to identify implementation factors from the perspective of practice
20 pharmacists and prioritise them for intervention, and (2) to identify potentially effective, acceptable and 
21 feasible strategies to support P-DQIP implementation.
22
23 Methods
24 Theoretical framework and study design
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71 The study design draws on guidance on using the ‘Behaviour Change Wheel (BCW)’ [19] (figure 1). The BCW 
2 is based on the Capability-Opportunity-Motivation-Behaviour (COM-B) change model, which identifies six 
3 broad influences on behaviour (physical and psychological capability, social and physical opportunity, 
4 reflective and automatic motivation). The linked Theoretical Domains Framework (TDF) [20] consists of 14 
5 overarching domains providing a more granular analysis of the influences on behaviour. The BCW and TDF 
6 have been extensively used to design interventions targeting health care professionals’ behaviour [21, 22].
7
8 The intended process by which drug related harm can be prevented in P-DQIP is shown in figure 2. Based 
9 on this, the behaviour to be targeted by the P-DQIP intervention was defined as pharmacists’ management 
10 of DTRs identified by the P-DQIP tool. To achieve this, pharmacists need to accomplish the following key 
11 tasks: (a) make clinical decisions on whether and which medication changes are appropriate; (b) 
12 collaborate with other clinicians to agree and implement a DTR management strategy; (c) embed the P-
13 DQIP work into their work routine. Most pharmacists would opportunistically conduct clinical medication 
14 reviews as part of their existing roles. However, pro-actively identifying g patients with DTRs was a new 
15 element that was expected (as a minimum) to increase the volume of pharmacists’ medication reviews and 
16 the frequency of pharmacist-GP interaction. 
17
18 To address objective 1, we conducted semi-structured face-to-face interviews with practice pharmacists 
19 using an interview topic guide based on the TDF, and then prioritised TDF domains for intervention. For 
20 objective 2, we mapped candidate intervention functions (i.e. mechanisms by which an intervention can 
21 change behaviour) to prioritised TDF domains using the ‘Behaviour Change Wheel’ [19, 23]. We used this 
22 mapping to identify suitable intervention functions, behaviour change techniques (BCTs) (i.e. the smallest 
23 ‘active ingredients’), and policies (i.e. avenues through which an intervention is delivered) [23, 24, 25] via 
24 consensus discussion within the research team. We agreed the final intervention content and delivery 
25 formats with local stakeholders (one senior practice pharmacists from each of three locality teams). 
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2 Subjects and setting
3 NHS Tayside has a total of 64 general practices serving a population of 425,000 residents with a median list 
4 size of 6,415 (range 1,796 to 13,044) patients across all practices. General practices are organised 
5 geographically into three Health and Social Care Partnerships (HSCPs) and 12 ‘clusters’, each cluster 
6 comprising between two and eight practices, who meet regularly to discuss quality improvement work. 
7 Each practice has at least one practice pharmacist representative, normally working in more than one 
8 practice. Their roles in these practices vary, but usually include cost-saving work (e.g. switching patients to 
9 less expensive but therapeutically equivalent medicines) as well as undertaking complex clinical medication 
10 review. We purposively sampled NHS employed practice pharmacists aiming to include pharmacists from 
11 each of the three HSCP (reflecting pharmacy management structure) and with a range of working 
12 experience as practice pharmacists (which we anticipated to influence perceptions of implementation 
13 barriers). The NHS Tayside health board approached a total of 18 practice pharmacists on our behalf by 
14 email (including participant information sheet) asking them to get in touch with the research team if they 
15 were interested in participating. Of the pharmacists approached, eight worked in HSCP 1, five in HSCP2 and 
16 five in HSCP 3. Twelve had more than five years working experience (reflecting larger numbers of 
17 pharmacists working in HSCP 1 and a disbalance towards more experienced practice pharmacists in NHS 
18 Tayside at the time of the study). The study was approved by the University Research Ethics Committee of 
19 the University of Dundee (REC reference number: 2016017_Toma) before any participant was approached.
20
21 Data collection
22 The interview topic guide (see additional file 1) was drafted using the 14 domains of the TDF [20], piloted 
23 with three practice pharmacists and optimised iteratively to address all TDF domains and to minimise 
24 multiple questions yielding similar answers. The two interviewers also exchanged experiences after each 
25 interview, and iteratively amended the topic guide as required.
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91
2 Semi-structured interviews were conducted by two postdoctoral research fellows (one male [JT], one 
3 female [MT]) with backgrounds in health psychology and previous experience in conducting semi-
4 structured interviews. The interviews were conducted between December 2016 and March 2017 and took 
5 place in the pharmacists’ place of work. The researchers had no prior relationships with any of the 
6 participants. The interviewers started the interview by providing background on the aims of P-DQIP and 
7 pre-specified components (including paper mock-ups of the core functionalities of the P-DQIP informatics 
8 tool, namely case finding of patients with high-risk prescribing and review facilitation). Participants’ 
9 perceptions of P-DQIP implementation factors were subsequently explored using the topic guide where it 
10 was tweaked iteratively as needed after each interview (depending on the exchange of experiences 
11 between the researchers). Interviews were audio-recorded and transcribed verbatim by a professional 
12 transcription service. The researchers also cross-checked a subsample of four transcripts alongside their 
13 audio recordings to ensure accuracy of transcribing. All audio recordings were stored securely in 
14 accordance with institutional policies. 
15
16 Data analysis
17 Data analysis was conducted by the core research team (JT, MT, TD) using NVivo 11 (for initial identification 
18 of relevant quotes) and MS Excel (for coding of quotes identified as relevant).
19
20 Identifying implementation factors (objective 1)
21 Following a familiarisation process, data analysis was conducted in four steps. 
22
23 The first step applied the framework method [21] using a deductive approach to code identified 
24 implementation factors in relation to COM-B and TDF coding. A coding guideline (see additional file 2) was 
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10
1 iteratively developed and applied by two coders (JT and MT). All quotes were then coded by both 
2 researchers using this guideline, with disagreements resolved by consensus discussion. 
3
4 The second step inductively developed a coding frame to identify specific beliefs among quotes coded to 
5 each TDF domain in step one. The coding frame was subsequently applied independently by two 
6 researchers (TD and JT), and disagreements were resolved by discussion.
7
8 The third step used consensus discussion to identify ‘expected barriers’ to P-DQIP implementation. An 
9 expected barrier was defined as a hindrance to P-DQIP implementation, which the interviewed pharmacist 
10 described as likely to occur in his or her own practice (rather than merely describing it as a relevant factor). 
11
12 The final step explored links between theoretical domains. 
13
14 Prioritisation of implementation factors and mapping of intervention components (objective 2)
15 In order to prioritise theoretical domains to be targeted by P-DQIP, we considered (as a crude guide) for 
16 each P-DQIP implementation factor within each theoretical domain: (a) how often it was coded; (b) how 
17 many participants it was coded for; (c) how often it was identified as an ‘expected barrier’, and (d) how 
18 feasible it was to address it as part of the P-DQIP intervention. 
19
20 The prioritised theoretical domains were mapped onto components of the Behaviour Change Wheel (BCW) 
21 [20]. Apart from being potentially effective, prospective intervention components needed to be acceptable 
22 and feasible in the existing NHS context, which meant they had to be (1) deliverable by existing NHS staff 
23 with minimal training; (2) deliverable with minimal disruption to primary care clinicians’ routine work; and 
24 (3) involve minimal cost to the NHS. These criteria guided a stepwise review of potential intervention
25 components by the core research team (JT, MT and TD), in which we first identified suitable intervention 
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1 functions among those mapped to each TDF domain in Michie et al’s mapping matrix [23]. We then used 
2 the matrices linking intervention functions to policy categories [24] and intervention functions to behaviour 
3 change techniques [25]. Through consensus discussion, which involved practitioners with substantial 
4 experience in the health service, ideas on how to address identified barriers were explored until a 
5 consensus was reached before potential delivery mechanisms were agreed and intervention components 
6 drafted. The draft was subsequently presented to three HSCP pharmacy leads in a face-to-face meeting, 
7 where the final intervention components and delivery formats were then finalised.
8
9 Patient and public involvement
10 Feedback on the P-DQIP implementation strategy was sought from two public self-selected representatives 
11 from NHS Tayside who had an interest in research on polypharmacy and risky prescribing within primary 
12 care. They attended research team meetings to advise on the project identifying which components would 
13 benefit patients the most based on their own experiences of polypharmacy.
14
15 Results 
16 Participants
17 Fourteen of the 18 pharmacists approached were recruited (4 did not reply after two reminders). 
18 Participants worked in practices in HSCP 1 (n=7), HSCP 2 (n=5), and HSCP 3 (n=2). Most pharmacists (n=11)
19 had over 5 years’ experience as practice pharmacists and most (n=10) worked in two or more practices. 
20 Two researchers (MT and JT) conducted seven face-to-face interviews each and interviews lasted from 30 
21 minutes to one hour. Data saturation was reached after 12 interviews. The additional interviews were 
22 conducted before the point of data saturation was established.
23
24 Identified implementation factors (Objective 1) 
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1 A total of 211 quotes (i.e. pieces of text judged as part of the same argument or thought) were identified as 
2 relevant to the target behaviour. The quotes represented thirteen of the theoretical domains (all except 
3 ‘intentions’, which were defined as explicit expressions of commitment or lack thereof, which were less 
4 likely given that the intervention was hypothetical at the point of interview) and encompassed five COM-B 
5 constructs (all except ‘physical skills’) (see Table 1 for sample quotes). In the following, we report findings 
6 organised by key pharmacist implementation tasks as outlined above, namely: (a) clinical decision making; 
7 (b) collaboration with other clinicians; (c) embedding the P-DQIP work in work routines.
8
9 Task 1: Clinical decision making 
10 Most pharmacists identified up-to-date pharmaco-therapeutic knowledge (knowledge; quote 1) as being 
11 essential to managing DTRs appropriately. Although participants generally felt their undergraduate 
12 education equipped them with the necessary knowledge and skills, some highlighted the need for selective 
13 ‘upskilling’ to manage infrequent/unfamiliar DTRs (Skills; quote 3). Having been shown the functionalities 
14 of the informatics tool, pharmacists expressed that it could help direct attention to DTRs, which may 
15 otherwise be overlooked (Memory, attention and decision-making;quote 5). Pharmacists’ confidence in 
16 clinically managing drug therapy risks appeared strongly associated with relevant experience of working as 
17 a practice pharmacist (Beliefs about capabilities, quote 6). However, several pharmacists identified 
18 complex therapeutic scenarios that required discussion by the wider multidisciplinary team irrespective of 
19 experience and skill (Beliefs about capabilities; quote 7). Some pharmacists felt their limited knowledge of 
20 patients’ personal circumstances prevented them from making decisions on DTRs independently. 
21 (Knowledge, quote 2). Several pharmacists highlighted their role was to advise or recommend a course of 
22 action to manage DTRs, but that the ultimate decision lay with other professionals (professional/social role 
23 and identity; quote 12). A few pharmacists expressed anxiety about making certain clinical decisions 
24 independently (Emotion; quote 8), while others highlighted that such independence could lead to a higher 
25 level of professional satisfaction (Goals; quote 23). 
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1
2 Task 2: Collaboration with other clinicians
3 Most felt that for pharmacists to lead on DTR management in a particular practice, familiarity with practice 
4 processes and systems (knowledge, quote 9) was essential. Interpersonal skills (skills, quote 10). Actual 
5 experience of working with other clinicians in the practice (social influences, quote 13) was seen as crucial 
6 to win or maintain their trust. Personal self-confidence (as a character trait) was deemed important when 
7 engaging with other clinicians in managing DTRs (beliefs about capabilities, quote 11). Some pharmacists 
8 reported to have accomplished a good working relationship with other clinicians in the practice (social 
9 influences; quotes 13, 14). However, despite efforts to integrate with practice teams, others felt that GPs 
10 perceived their primary role as a resource for cost-cutting (social influences; quote 15) and that GPs 
11 scepticism about their clinical skills (social influences, quote 16) were barriers to pharmacist-GP 
12 collaboration in DTR management. Feelings of frustration on misconceptions of the pharmacists’ role 
13 (social influences, quote 15) and lack of trust in their capabilities by practice staff were evident (social 
14 influences, quote 16). Some believed that GP staff shortages limited opportunities to discuss and agree on 
15 strategies on how best to manage DTRs (Environmental context and resources; quote 31). 
16
17 Task 3: Embedding the P-DQIP work into work routines
18 Most pharmacists appeared motivated to implement the P-DQIP work. Several pharmacists expressed that 
19 medication reviews and patient safety were strongly aligned with their professional identity 
20 (Professional/Social Role and Identity. quote 18), and valued the P-DQIP work as a potential means to 
21 achieve further recognition as clinicians by the wider primary care team (Goals. quote 22). Half also 
22 expected tangible clinical benefits for patients (Beliefs about consequences. quote 20). Most pharmacists 
23 were positive that using the P-DQIP informatics tool would support them in managing DTRs, despite 
24 expectations of increased workload (Optimism. quote 21). Although the majority of pharmacists thought 
25 that the informatics tool would make the review process more efficient and structured (quote 19), most 
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14
1 expected difficulties in fitting review of patients proactively identified by the P-DQIP informatics tool into 
2 their work routines. A prominent theme was the perceived high workload of routine tasks (Environmental 
3 context and resources; quotes 27 to 29), including cost-saving projects and medicines reconciliation after 
4 hospital discharge, which could at least partly be delegated to pharmacy technicians (Environmental 
5 context and resources; quote 30). 
6
7 As strategies to engage pharmacists in the P-DQIP work, some mentioned there was a need for protected 
8 time (quote 17). Several pharmacists expected that prompts to specific DTRs delivered by the P-DQIP tool 
9 during reviews could encourage them to address such DTRs systematically at practice level (Reinforcement; 
10 quote 24). Feedback and peer comparison (e.g. on reductions in targeted prescribing) were viewed 
11 favourably as strategies to encourage and maintain pharmacists’ engagement (quote 26). In contrast, 
12 purely quantitative targets set by line managers (e.g. a minimum number of reviews per week) were 
13 viewed as a disincentive to address DTRs that are more complex or time consuming to manage (quote 25).
14
15 Interactions between TDF domains
16 While participants generally believed pharmacists’ professional skills (knowledge and skills, professional 
17 role and identity) enabled them to undertake the P-DQIP work, self-perceived levels of capability (beliefs 
18 about capabilities) varied depending on experience. Although pharmacists expressed a personal and/or 
19 professional desire to engage in the P-DQIP work (beliefs about consequences), fitting the work into their 
20 routines (behaviour regulation), was limited by competing demands on pharmacists’ time imposed by NHS 
21 line managers and practices (environmental context and resources). Nevertheless, pharmacists believed 
22 that the informatics tool could make the process of identifying and reviewing DTRs more efficient (beliefs 
23 about consequences) and effective (memory, attention and decision making). In terms of social influences, 
24 practices’ expectations of the pharmacists’ role (clinical versus cost cutting work), their skills, and the level 
25 of trust in their profession and as individuals were all reported to influence beliefs about capabilities. These 
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1 could also be limited by a lack general practitioner availability to agree on medication changes 
2 (environmental context and resources), which in turn may be driven by GPs’ competing demands and/or a 
3 lack of interest in DTR management and/or collaboration with pharmacists (social influences).
4
5 Prioritisation of theoretical domains and mapping of intervention components (objective 2)
6 Table 2a and 2b show theoretical domains prioritised and not prioritised for intervention for each of the 
7 three key pharmacist tasks as above. In the following, we outline the rationale for prioritisation and the 
8 selection of intervention functions, BCTs and policies for prioritised theoretical domains for each task.
9
10 Task 1: Clinical decision making
11 In order to support pharmacists’ capability to make appropriate clinical decisions, we prioritised the TDF 
12 domains skill, memory/attention/decision making, and reinforcement. The pre-specified functionalities of 
13 the P-DQIP informatics tool included case finding patients with DTRs (BCT: prompts/cues targeting 
14 memory/attention/decision making) as well as prompts to specific DTRs in individual patients (BCT: 
15 Prompts/cues targeting reinforcement). In order to address varying clinical skills by pharmacist and by drug 
16 therapy risk, it was decided that we would supplement DTR prompts by brief guidance on the management 
17 of each DTR within the P-DQIP informatics tool and provide more detailed evidence and guidance around 
18 targeted DTRs in an accompanying manual (BCTs: instructions on how to perform a behaviour targeting 
19 skill). Although potentially more effective, we considered it unfeasible to provide (and for pharmacists to 
20 attend) comprehensive face-to-face education and training for the broad range of targeted DTRs within 
21 currently available resources. 
22
23 Task 2: Collaboration with other clinicians
24 A key rationale for designing a pharmacist-driven intervention was to enhance the capacity of primary care 
25 teams to systematically manage DTRs. A pre-requisite to realising such benefits is that GPs are willing to 
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1 delegate DTR management tasks to pharmacists, which depends on trust. On the other hand, some 
2 involvement of GPs in DTR management continues to be required, not least because of legal constraints 
3 (not all pharmacists are licensed prescribers).  The discrepancies between their own and GPs’ perceptions 
4 of their professional role reported by some pharmacists and a lack of trust in their clinical skills and 
5 capability are potential barriers to P-DQIP implementation, and so is a lack of engagement of GPs in DTR 
6 management and interest in collaboration with pharmacists. While P-DQIP could increase opportunities to 
7 develop trust, it is highly unlikely that a single intervention will change such perceptions much. To begin to 
8 promote collaborative working between GPs and practice pharmacists in general practices, we considered 
9 formal inter-professional education and action planning exercises. However, additional costs (GP locum 
10 fees), and poor attendance because of current GP staff shortages may prevent them from successful 
11 implementation. We have therefore decided to target pharmacists and GPs separately. We plan to support 
12 pharmacists by providing a platform for more experienced pharmacists to provide support to their peers. 
13 Pharmacists affiliated with practices in the same cluster will therefore participate in a moderated workshop 
14 to reflect on potential implementation barriers in their own settings and jointly develop strategies to 
15 overcome them, including an analysis of inter-professional or inter-personal  barriers and strategies to 
16 engage GP’s and win their trust (BCT: problem solving targeting skill). Additionally, we plan to engage GPs 
17 via strategies that have been successfully applied in the GP-led DQIP intervention [26, 27], namely 
18 encouraging practices to use the P-DQIP tool for systematic DTR management (Policy: 
19 communication/marketing targeting social influences), provision of a web-based tool to enable practices to 
20 monitor trends in patients with targeted DTRs over time (BCT: Self-monitoring targeting social influences) 
21 as well as small financial incentives (BCT: restructuring the social environment targeting social influences). 
22 Rather than an unconditional participation fee (as in DQIP), payment (GBP 450) in P-DQIP will be 
23 conditional on practices (a) nominating a lead GP for P-DQIP, (b) providing evidence of a meeting between 
24 the lead GP and practice pharmacist, in which a strategy for initiating and maintaining the practice’s 
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1 engagement in the P-DQIP work is agreed, and (c) providing evidence of using the P-DQIP tool to monitor 
2 their progress in reviewing and reducing targeted prescribing. 
3
4 Task 3: Embedding the P-DQIP work into pharmacists’ work routines
5 The competing demands on pharmacist time inflicted on pharmacists by their health board employers as 
6 well as practices were a prominent theme in pharmacist interviews. A health board policy protecting 
7 pharmacist time for the P-DQIP work (as requested by one pharmacist) proved unfeasible. As an 
8 alternative, we therefore aim to support pharmacists through training in time management (BCT: Action-
9 planning targeting skill) and goal setting (BCT: Goal setting targeting behavioural regulation) as part of a 
10 moderated workshop (see above). Since we expect the number of patients with DTRs identified by the 
11 informatics tool to exceed those manageable in a single effort, a step-wise approach to implementation 
12 will be adopted, where a smaller number of DTRs will be targeted initially in order to support pharmacists 
13 in planning and structuring the workload over time (policy: guideline targeting environmental context and 
14 resources). In order to maintain pharmacists’ engagement over time, we will additionally provide IT 
15 functionality to facilitate self-monitoring of review activity and trends in the numbers of patients with 
16 targeted DTRs (BCT: Self-monitoring of behaviour targeting behavioural regulation). In order to emphasize 
17 the importance that health boards assign to DTR management, line managers will request that pharmacists 
18 report on their DTR management activity on a monthly basis as they are currently doing for other routine 
19 tasks (BCT: Monitoring of behaviour by others targeting reinforcement). 
20
21 Figure 3 shows a diagram depicting the design of the P-DQIP intervention, which in the broadest terms 
22 comprises two elements aiming to (1) facilitate the identification and review of patients with DTRs and (2) 
23 maintain professional engagement and collaboration in this process. 
24
25 Discussion 
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1 Summary of findings
2 We systematically explored key implementation of a data and pharmacist driven DTR management system 
3 (P-DQIP) from the perspective of NHS employed pharmacists (who will implement the intervention). 
4 Despite drawing on previously tested intervention components (an informatics tool with core 
5 functionalities [DQIP trial], and a pharmacist-led review model [PINCER trial]), we anticipated likely 
6 implementation and adoption challenges arising from the broadened scope and number of targeted 
7 patients, and from altering and/or adding to the work of NHS employed pharmacists with established roles 
8 in general practices. Consistent with the Medical Research Council (MRC) complex interventions framework 
9 [28], we therefore considered it essential to better understand such challenges and identify potential 
10 strategies to address them before embarking on a wider implementation and evaluation of effectiveness. 
11 We used the TDF to comprehensively examine factors that could mediate (i.e. support or hinder) P-DQIP 
12 implementation [20]. Pharmacists felt that the core functionalities of the P-DQIP IT tool could address 
13 barriers relating to memory/attention and decision making (via prompts/cues). However, additional BCTs 
14 and/or policies were judged necessary to overcome barriers relating to five other TDF domains (skills, 
15 behavioural regulation, reinforcement, environmental context and resources, and social influences). Based 
16 on the interview data, these intervention components had the potential to positively influence 
17 pharmacists’ beliefs in their capabilities, which were found to be key to the implementation of a DTR 
18 management system that is pharmacist-driven. 
19
20 Comparison to previous research
21 The notion that pharmacists are an underutilised clinical resource has stimulated a considerable amount of 
22 research on pharmacist-led interventions in primary care.  Most previous evaluations, however, focus on 
23 ‘non-dispensing’ or ‘cognitive’ services delivered by community pharmacists (as opposed to practice 
24 pharmacists employed by a health care funder, such as the NHS) and the design of interventions found in 
25 such evaluations are rarely explicitly theory-based [29]. An exception is a qualitative study by Cadogan et al 
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1 [22], in which the authors used the TDF – similar to this study – to guide selection of intervention 
2 components targeting prescribing (by GPs) and dispensing (by community pharmacists) for older people 
3 with polypharmacy in primary care. The theoretical domains prioritised for intervention by Cadogan et al 
4 broadly match the ones selected in this study, and all but one BCT (‘social processes of 
5 encouragement/support’) selected by Cadogan at al were also selected by us. Nevertheless, a noteworthy 
6 difference is our prioritisation of reinforcement, which reflects our intention to facilitate the sustained 
7 implementation of the P-DQIP intervention in NHS Scotland, rather than designing an intervention for 
8 evaluation in a randomised controlled trial. For the same reason, we additionally include a number of BCTs 
9 and locally agreed policies to encourage and maintain pharmacist-driven DTR management (goal setting, 
10 self-monitoring of behaviour, monitoring of behaviour by others, promotion/marketing, guidelines). A 
11 further difference is our focus on informatics tools as a delivery mechanism for BCTs (cues/prompts, 
12 education, feedback), which was enabled by our opportunity to build on medicines management software 
13 which is available in all Scottish GP practices, and which can interrogate practices’ electronic medical 
14 records and generate reports. 
15
16 Strengths and limitations
17 This study uses a theory-based systematic approach to design a strategy to support the implementation of 
18 a pharmacist-driven DTR management process in UK general practice. By describing our stepwise approach, 
19 starting with the specification of the target behaviours, identification and prioritisation of implementation 
20 factors, and finally, the selection of BCTs and policies, we provide complete transparency in our choice of 
21 intervention components optimising them for effective implementation. We used the framework method 
22 applying the widely used COM-B and theoretical domains framework in conjunction with a systematic 
23 coding process, which was produced from a subset of the interviews. Further, we collaborated closely with 
24 local stakeholders to ensure that intervention components were feasible, acceptable and deliverable by 
25 existing NHS staff.
BMJ Open
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
20
1
2 The main limitation of the study is that our findings may only apply to the context in which it was 
3 conducted, and therefore may not represent the perspectives of practice pharmacists in general. 
4 Specifically, all interviewed pharmacists had established roles within their affiliated practice(s) and most 
5 had more than five years of experience working as practice pharmacists meaning that perspectives could 
6 be different in contexts where primary care pharmacy is less well established. Nevertheless, the pro-active 
7 identification, review and management of DTRs as the target behaviour of the P-DQIP intervention, was 
8 novel to all participants, and we identified implementation barriers (e.g., practices’ trust in pharmacists’ 
9 skills) that would be expected to be more prominent among pharmacists with less working experience in 
10 general or in the practices they work in. It is also possible that the prioritisation of theoretical domains and 
11 selection of intervention strategies was biased by our previous experience of developing successful 
12 prescribing safety interventions in primary care [12]. However, by systematically considering intervention 
13 strategies based on mapping recommendations, we minimised the risk of omitting relevant theoretically 
14 underpinned alternative or additional strategies. Furthermore, the theoretical domains prioritised for 
15 intervention in this study broadly matched those identified in a similar study targeting community 
16 pharmacists [22], which, taken together, affirms their relevance to current policies which aim to extend 
17 pharmacists’ clinical roles in primary care. Although the intervention design draws on an enhanced local 
18 infrastructure, implementing the IT components of the intervention would be possible (in principle) in any 
19 health care setting, where electronic health records are used. The study used experiential alongside 
20 theoretically underpinned design of intervention strategies. Although a pragmatic approach to intervention 
21 development, we acknowledge that it limits the ability to examine the respective contributions of theory 
22 and experience in driving behaviour change. 
23
24 Conclusions
BMJ Open
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
21
1 The findings of this study are of particular relevance to the UK context, which has recently seen substantial 
2 investment in practice pharmacist posts to improve medicines management and reduce GP workload. Our 
3 study suggests that pharmacists’ beliefs in their capabilities is a key factor influencing their capacity to 
4 extend their clinical roles, and this was, in turn, limited by their existing skill sets, available resources 
5 (including managing time in the face of conflicting demands), and under-developed working relationships 
6 with general practitioners. 
7
8 The design of the optimised P-DQIP implementation strategy demonstrates that providing tools and 
9 training pharmacists alone is likely to be insufficient to sustain pro-active identification and management of 
10 patients with DTRs by teams of pharmacists and GPs. Aligning pharmacists’ roles with the stepwise 
11 attainment of measurable practice level performance goals may be one way of stimulating and maintaining 
12 concerted action by these professionals. 
13
14 More broadly, comparison of the optimised P-DQIP intervention to an intervention with similar objectives 
15 developed by Cadogan et al highlights that intervention design choices are influenced by local 
16 implementation challenges as well as local opportunities to address them. While this may compromise the 
17 applicability of evaluation findings in other health care contexts, process evaluations can be used to help 
18 understand both the relative importance of intervention components and their interactions with local 
19 implementation context.
20
21 The P-DQIP intervention will be implemented in all practices in one NHS Scotland health board and 
22 evaluated in an interrupted time series study with parallel process evaluation to examine its 
23 implementation and effectiveness. 
24
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1 COM-B: Capability, Opportunity, Motivation and Behaviour
2 TDF: Theoretical Domains Framework
3 BCTs: Behaviour Change Techniques
4 DQIP: Data Driven Quality Improvement in Primary care
5 P-DQIP: Pharmacist and Data Driven Quality Improvement in Primary care
6 DTR: Drug Therapy Risk  
7 NSAIDs: Non-steroidal Anti-Inflammatory Drugs (NSAIDs)   
8 HSCP: Health and Social Care Partnership     
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Table 1: Sample quotes from pharmacists mapped to implementation tasks and relevant theoretical domains 
COM-B construct
TDF domain 
Specific belief (linked to 
implementation factor) 
Quote No. 
Sample quote
Count of relevant 
quotes 
(count reflecting
‘expected’ barriers)
Count of participants 
with relevant quotes 
(count reflecting 
‘expected’ barriers)
TASK 1: APPLYING CLINICAL JUDGEMENT
COM-B construct: Psychological capability
TDF domain: Knowledge
Specific belief: 
Therapeutics
1. “… your therapeutics has got to be up to scratch”. (Pharmacist 09) 15 (0) 3 (0)
Specific belief: Patient 
preferences/ 
circumstances
2. “If I don’t know the patient I would speak to the GP because I might be making suggestions
that he’s tried before. He’ll say, oh there’s no point in trying to stop that because, I’ve tried
that a million times before”. (Pharmacist 10)
4 (1) 4 (1)
TDF domain: Skill
Specific belief: Clinical 3. “you might decide oh I want to look at those indicators but maybe I don’t [feel] confident
enough to make the changes myself, or I would be then having to refer back to other
practitioners, so you might want to up-skill your clinical skills in that…” (Pharmacist 06)
13 (4) 8 (4)
COM-B construct: Reflective motivation
TDF domain: Memory, attention and decision making
Specific belief: Decision 
making
4. “I was hoping that the P-DQIP tool would help identify the patients that need to come in, to
help to review them, because at the moment you’re sitting with 6,000 patients on repeat
meds and where do you start”. (Pharmacist 08)
10 (0) 5 (0)
Specific belief: 
Attention
5. “That [the informatics tool] would really help, ‘ cause you may not have thought about this
interaction or something, you may just be prescribing, you might not have thought about the
fact you can't put these two drugs together or perhaps the patient’s age or whatever”.
(Pharmacist 14)
5 (0) 4 (0)
TDF domain: Beliefs about capabilities
6. “I’ve been a practice pharmacist for a long time, so, I’ve seen a lot of cases and worked
with a lot of patients with a lot of different conditions and sometimes that confidence, it just
comes with experience doesn’t it?” (Pharmacist 09)
17 (4) 11 (3)Specific belief: 
Professional confidence
7. “I wouldn’t be confident in going and stopping some of the anti-psychotics and
schizophrenic patients and things like that if they were under mental health”. (Pharmacist 08)
COM-B construct: Reflective motivation
TDF domain: Emotion
Specific belief:
 Anxiety
8. “I feel a greater weight of responsibility when I am actually prescribing for somebody, it
takes me quite a lot to put the pen to paper to actually do the prescription”. (Pharmacist 13)
2 (0) 2 (0)
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TASK 2: COLLABORATION WITH GPS 
COM-B construct: Psychological capability
TDF domain: Knowledge
Specific belief: Task 
environment
9. “You’ve got […] to understand how a practice works and how it interacts with other care
environments …” (Pharmacist 09)
15 (0) 9 (0)
TDF domain: Skill
Specific belief: 
Interpersonal
10. “You're going to have to get to know the people that you're working with, and I think for
the first little while you might say right I'll speak to the GPs about the changes first of all, just
to demonstrate that you're capable, you're not going to do something dangerous and you're
not going to just spend all your time [..]  telling the patients that the GPs are rubbish …”
(Pharmacist 11)
15 (0) 8 (0)
COM-B construct: Reflective motivation
TDF domain: Beliefs about capabilities 
Specific belief: Personal 
self-confidence 
11. “I'd be quite happy to say, yeah, I would lead on that in the practice; I'd quite happily
take that … I'd take it to the GPs and say right, this is what we're going to do”. (Pharmacist
11)
4 (0) 4 (0)
TDF domain: Professional/social role and identity
Specific belief: 
Professional
boundaries
12. “I will make my recommendations, they’ll be discussed round the table by various
professionals and then there’ll be a decision made as to whether they’re appropriate actions
or not and how they’re going to be implemented”. (Pharmacist 09)
7 (0) 4 (0)
COM-B construct: Social opportunity
TDF domain: Social influences
Specific belief: 
Interpersonal trust
13. “My GPs are like that with me because I’ve been with them for a long time and they
know what I can do and what I don’t. They know that if I’m in doubt about anything I would
go and ask them. If you see what I mean? They’d be supportive of me, whereas I’m not so
sure if I went someplace else how that would be without those GPs knowing that Pharmacist
there”. (Pharmacist 08)
21 (2) 13 (1)
Specific belief: Practices’ 
staff interest in 
collaboration
14. “We have weekly meetings, multidisciplinary meetings and we discuss vulnerable
patients who are maybe tinkering on the edge of needing admission to hospital and maybe
just need a little bit more support at home”. (Pharmacist 10)
27 (4) 8 (3)
Specific belief: Practices’ 
perception of pharmacist 
role
15. “I’m concerned now that they look at me and say, oh she’s just here to, help cut costs,
because I think they can… because it’s such a big thing and I don’t think it’s me that’s doing
it I think it’s the management that are doing it and it’s filtering through to them … I don’t
feel comfortable with that because I think we’re there as a quality thing. Obviously cost does
come into it, but, that does concern me to a certain extent”. (Pharmacist 02)
8 (3) 5 (3)
Specific belief: Practices’ 
perception of pharmacist 
skills
16. “If every decision that they're making is questioned and the pharmacist then feels that
they're unwilling to make any changes because it's just going to come back and hit them in
the face kind of thing”. (Pharmacist 13)
12 (2) 9 (2)
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TASK 3: FITTING P-DQIP INTO WORK ROUTINES
COM-B construct: Psychological capability
TDF domain: Behavioural regulation
Specific belief: 
Action/work planning
17. “If we get that sort of system set up, that would be fine, you know, it’s not that kind of
thing I’m worried about. It’s actually having the protected time to do it”. (Pharmacist 08)
17 (1) 10 (1)
COM-B construct: Reflective motivation
TDF domain: Professional/social role and identity
Specific belief: 
Professional identity
18. “The core of our job is patient safety and these drugs are obviously very, very risky to
patients, so I think they [other pharmacists] should be engaged”. (Pharmacist 12)
11 (0) 6 (0)
TDF domain: Beliefs about consequences
Specific belief: Review 
process 
19. “The positive would be for me, it would make polypharmacy reviews a lot easier and give
you areas to focus on which is good”. (Pharmacist 12)
24 (0) 12 (0)
Specific belief: Patient
benefit
20. “Helping to reduce the high risk prescribing basically and help some of the patients out
there that shouldn’t be on drugs that they are currently on and harming them. Well, you’re
going to stop them falling, ending up in hospital. Some of the dreadful side effects that some
of the drugs have. A lot of them don’t realise they’ve got a dry mouth because of their
drugs…” (Pharmacist 08)
6 (0) 6 (0)
TDF domain: Optimism
Specific belief: Positive 
attitudes
21. “Yes, it is something else to do but, if we do this it will hopefully help pre-empt problems
in the long run”. (Pharmacist 9)
8 (0) 7 (0)
TDF domain: Goals
Specific belief: 
Professional 
recognition
22. “When I did the Polypharmacy pilot I was working late every night because I was doing
this really in addition to my other work.  … I wanted it to be done properly so I invested a lot
of my energy and time to doing that … maybe I wouldn’t do it in so much depth now but, at
that point, I did want to know… because we were at the beginning.   The first time I’d work
with the Consultant and the GP together so I wanted to pre-empt any questions I would be
asked”. (Pharmacist 03)
13 (0) 9 (0)
Specific belief: 
Professional satisfaction
23. “[in a previous multidisciplinary project on polypharmacy] ... the consultant from
Medicine for the Elderly was, very much taking the lead, … so there was a certain amount of
professional satisfaction but not, not the same as you would, if you were actually doing the
review on your own”. (Pharmacist 13)
1 (0) 1 (0)
TDF domain: Reinforcement
Specific belief: 
Prompts/cues
24. “as you're doing it that would be a way to prompt you, and as I said if you see one you
might go and search for patients on say, I mean … there's some computer systems where
they flag up interactions and from that you may think oh well, OK, this seems to be coming
up a lot, I can go and search and see if there's any more patients and then you would then
set up and probably go, and go and have a look”. (Pharmacist 14)
8 (0) 5 (0)
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Specific belief: 
Goal/target setting
25. “… I don't know, setting people targets … I wouldn’t, I would steer away from that in like,
you know, in the practice …, 'cause I know they've tried it … and it, it's not fabulously helpful.
You’d pick the easy ones wouldn’t you”. (Pharmacist 01)
3 (0) 3 (0)
Specific belief: 
Peer comparison
26. “There's always a list and nobody wants to be at the bottom, so it's nice to see yourself …
we've improved and got better, you sort of, you can rank yourself against the others and see
how well you're doing...” (Pharmacist 03)
7 (0) 5 (0)
COM-B construct: Physical opportunity
TDF domain: Environmental context and resources
27. “We have to do cost-savings but sometimes, ... we may get asked just to drop some of
the work we do, safety work we do, and cost savings are always a, a priority”. (Pharmacist
01)
9 (6) 8 (5)Specific belief: 
Competing demands on 
time - health board
28. “It’s actually having the protected time to do it and not just asking us to do something
else at the end of a really, really long day”. (Pharmacist 08).
Specific belief: 
Competing demands on 
time - practices
29. “And then I went away on three weeks’ holiday and I’ve come back and they said oh
we’re so pleased to see you [laughter]. The GP even stopped me in the car park and he says
oh, fantastic, he says, I can send my discharges your way now again, because they need
some help”. (Pharmacist 08)
1 (1) 1 (1)
Specific belief: Staff 
resources -pharmacy
30. “So this particular practice has a Prescribing Support Technician on a Thursday every
week doing work, because it's a high-cost practice, but like the practice that I came from
before that, didn’t have technician cover for months and so the cost-minimisation work has
just been done by me”. (Pharmacist 13)
5 (0) 3 (0)
Specific belief: Staff 
resources -practice
31. “At the moment, because of the lack of GPs in the practice, there’s not the appetite to
move forward with it because we could identify lots of patients and there’s just not the staff
to agree the changes that need to be made”. (Pharmacist 09)
5 (1) 4 (1)
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 Table 2a. Prioritised theoretical domains and mapping of intervention functions, policies and behaviour change techniques (BCTs) to support the three target 
behaviours
COM-B construct
TDF domain 
Specific belief (linked to 
implementation factor)
Relevance to pharmacist-driven 
management of DTRs
Intervention functions 
considered 
Behaviour change techniques/policies for selected intervention functions/   
Reasons for non-selection of intervention functions
TASK 1: APPLYING CLINICAL JUDGEMENT
COM-B construct: Psychological capability
TDF domain: Skill Clinical skills vary by pharmacist and 
type of drug therapy risk; 
Training  Instruction on how to perform a behaviour/modelling/
demonstration of behaviour: Provide brief and detailed written
guidance on managing drug therapy risks targeted by the P-DQIP
tool; demonstrate how to use the P-DQIP tool to identify and
manage DTRs
TDF domain: Memory, 
attention and decision 
making
Support in prioritising patients and 
identifying DTRs valued
Enablement  Prompts/cues: P-DQIP tool identifies patients with drug therapy risks
at practice level
COM-B construct: Automatic motivation
Environmental 
restructuring
 Prompts/cues: P-DQIP tool identifies drug therapy risks in individual
patients
Training  None: Not feasible
Incentivisation  None: Not feasible or acceptable
TDF domain: 
Reinforcement
Support in identifying DTRs at the 
point of review
Coercion  None: Not feasible or acceptable
TASK 2: COLLABORATION WITH GPS
COM-B construct: Psychological capability
TDF domain: Skill The quality of relationships between 
pharmacists and GPs varies; 
Training  Problem solving (to address interpersonal skills): Prompt pharmacists
to analyse interpersonal barriers for collaboration with GPs and
develop strategies to overcome them (e.g. to build trust)
COM-B construct: Social opportunity
TDF domain: Social 
influences
Practices’ trust in pharmacists’ skills 
varies; practices‘ perceptions of 
pharmacist’s role as mainly cost-
cutting limits collaboration in patient 
care; practices’ interest in P-DQIP 
Environmental 
restructuring
 Communication/marketing: Promotion of the P-DQIP tool among GP
clusters as a means to monitor and drive quality improvement in DTR
management
 Restructuring the social environment: Financial incentives for GP
practices to engage in P-DQIP work
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Enablement  Self-monitoring of behaviour (GP practices): Provide tools to
facilitate monitoring of review activity and trends in patients with
DTRs
Modelling  None: Not feasible because of the heterogeneity of social context
work is crucial but expected to be 
variable 
Restriction  None: Not feasible (although pharmacists thought a policy that
protects pharmacist time from other routine demands was deemed
desirable)
TASK 3: FITTING P-DQIP INTO WORK ROUTINES
COM-B construct: Psychological capability
TDF domain: Skill Challenge of fitting P-DQIP work into 
work routines
Training  Action-planning: Encourage pharmacist to make detailed plans on
how to introduce pharmacist-driven DTR management to practices
Training  Goal setting (behaviour): Encourage pharmacist to set themselves
achievable goals, eg conduct at least one review per day
 Action-planning: see under skills
TDF domain: Behavioural    
regulation
Pharmacists struggle to fit medication 
reviews in with their routine work; 
pharmacists will avoid or 
procrastinate reviewing patients with 
more complex drug therapy risks 
Enablement  Self-monitoring of behaviour (pharmacists): Provide tools to facilitate
monitoring of review activity and trends in patients with DTRs
COM-B construct: Automatic motivation
Environmental 
restructuring
 Monitoring of behaviour by others: Pharmacists will include their
DTR management activity in their monthly report to line managers
Training  None: Not feasible
Incentivisation  None: Not feasible or acceptable
TDF domain: 
Reinforcement
Pharmacists may not perceive P-DQIP 
reviews as a health board priority
Coercion  None: Not feasible or acceptable
COM-B construct: Physical opportunity
Training  Action-planning: see under skills
Restriction  None: Not feasible (although pharmacists thought a policy that
protects pharmacist time from other routine demands was deemed
desirable)
TDF domain: Environmental 
context and resources
Belief that health board demands for 
cost-saving work will conflict with P-
DQIP delivery; belief that practices’ 
demands on pharmacists’ work will 
conflict with P-DQIP delivery 
(especially when there is limited 
support from pharmacy technicians)
Environmental 
restructuring
 Guideline: Health board specifies priorities for the P-DQIP work that
initially contain the number of drug therapy risks to be targeted for
review by pharmacists
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 Table 2b. Relevant theoretical domains not prioritised for intervention to support the three target behaviours
COM-B construct
TDF domain 
Specific belief (linked to 
implementation factor)
Relevance to pharmacist-driven 
management of DTRs
Rationale for exclusion
TASK 1: APPLYING CLINICAL JUDGEMENT
COM-B construct: Psychological capability
TDF domain: Knowledge Knowledge of pharmacotherapy,
task environment, and patient 
preferences/ circumstances
Not prioritised for intervention, because reported limitations of pharmacists’ abilities appeared to 
relate more to managing DTRs (skill) rather than to gaps in pharmaco-therapeutic knowledge. It was 
considered unfeasible to change pharmacists’ knowledge of the task environment (requires 
experience) and of patient preferences/circumstances (requires patient contact)
COM-B construct: Reflective motivation
TDF domain: Beliefs about 
capabilities
Belief in own capabilities is influenced 
by perceived knowledge, skill, other 
work demands and support from 
practices, which is variable
Not prioritised for intervention since it would likely require an individually tailored intervention 
(infeasible). However, it was believed that this domain could be indirectly influenced by targeting 
skill, memory/attention/decision making, behavioural regulation, environmental context/resources 
and social influences
COM-B construct: Automatic motivation
TDF domain: Emotion Anxiety towards/professional 
satisfaction from autonomous decision 
making 
Not prioritised for intervention since mitigating anxiety would require an individually tailored 
intervention (infeasible); Enhancing professional autonomy deemed infeasible as part of the 
intervention 
TASK 2: COLLABORATION WITH GPS
COM-B construct: Reflective motivation
TDF domain: Professional/
social role and identity
Pharmacist shares responsibility 
for therapeutic decisions with other 
clinicians
Not prioritised for intervention. Although greater professional autonomy could facilitate P-DQIP 
implementation, it was deemed infeasible to enhance it as part of the intervention
TDF domain: Goals Professional recognition Not prioritised for intervention since aims of P-DQIP appeared to be aligned with personal goals
TASK 3: FITTING P-DQIP INTO WORK ROUTINES
COM-B construct: Reflective motivation
TDF domain: Beliefs about 
consequences
Impact on work processes and
 patient outcomes
Not prioritised for intervention since pharmacists appeared to quickly understand the differences to 
current work processes as well as potential advantages and disadvantages; it was deemed infeasible 
to change pharmacists’ perception of increased workload 
BMJ Open
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
33
TDF domain: Optimism Belief that P-DQIP work can be 
implemented despite increased 
workload
Not prioritised for intervention since it would likely require an individually tailored intervention 
(infeasible)
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Figure titles and legends 
Figure 1 title: The behaviour change wheel. Reproduced from reference [19]
Figure 2 title: Intended drug therapy risk management model with behaviours to be targeted by the P-DQIP informatics tool. 
Figure 2 legend: The dotted lines denote potential pathways, i.e. pharmacists may decide on a DTR management strategy with or without prior 
consultation with patients or other clinicians. DTR = Drug Therapy Risk; P-DQIP = Pharmacist and data-driven quality improvement in primary 
care 
Figure 3 title: Final components of the P-DQIP intervention.
Figure 3 legend: Components are colour coded in terms of which COM-B category they primarily target (red: psychological capability; yellow: 
automatic motivation; amber: reflective motivation; light green: physical opportunity; dark green: social opportunity). Delivery mechanisms and 
content are numbered and specified in text below.
(1) P-DQIP informatics tool integrated into existing Medicines management software [Scottish Therapeutics Utility]: (1a) Search engine to
identify patients triggering 18 composite and 69 individual indicators of drug therapy risks; (1b) Structured summaries of a patient’s ongoing
medical   problems, investigations and current medications; (1c) Highlighting of a patient’s identified drug therapy risks and brief
management instructions; (1b) Facility to run weekly reports on the number of medication reviews submitted via the P-DQIP tool, with
further details on medication changes, follow up actions and time taken; (1e) Web-based application allowing practices to compare levels
and trends of targeted prescribing to practices in their ‘cluster’, their HSCP and the health board
(2) Written educational material providing referenced evidence and guidance around targeted prescribing
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(3) Half-day workshop with pharmacists affiliated with practices in the same ‘cluster’, moderated by P-DQIP lead pharmacists. Introduction of
action planning instruments, goal setting and opportunity for pharmacists to  discuss anticipated implementation problems and solutions
(4) Phased implementation of the review work with initial focus on patients at increased risk of a small number of specific adverse drug events
(5) Request to attend routine meetings of GP clusters by P-DQIP lead pharmacists to promote the use of the P-DQIP informatics tool to identify
and facilitate the review of patients with DTRs and to monitor progress towards reducing targeted prescribing at practice and cluster levels
(6) Offer of payment of £450 per practice, which is conditional on providing evidence of conducting the following tasks: (a) Nominate a GP-lead
for P-DQIP; (b) GP-pharmacist meeting to assign roles and responsibilities in P-DQIP work; (c) ongoing support for pharmacists in managing 
DTRs identified by the P-DQIP tool; (d) number of patients with DTRs reviewed by the practice over the P-DQIP intervention period
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Topic guide 
Demographics 
• Please could you tell me a bit about yourself?
• How long have you been working as a pharmacist and how many practices do you currently
work in?
Introduction 
Polypharmacy and prescribing in older people have received a lot of attention recently. 
• Could you please tell me a little about your own experiences with reviewing the medication
of vulnerable people on multiple or risky medicines?
• Do you have any suggestions on how to best reduce risky prescribing?
Barriers/facilitators to identifying and managing patients identified by the 
informatics tool  
• What is your level of experience in conducting medication/polypharmacy reviews? How
often do you do them? (knowledge/skills)
• When exactly do you decide to conduct a medication/polypharmacy review? Prompt: In
which patients? In which situations? Why? (Memory, attention and decision processes)
• In your opinion, what exactly do you need to know in order to conduct a
medication/polypharmacy review? Prompt: Can you provide example of where knowledge
gaps could affect your ability to carry out an effective review? (knowledge/skills, beliefs
about capabilities)
• To which extent do you make decisions about medication changes independently (without
GP assistance)? How confident are you in doing so?  Prompts: Why/why not? Do you hold a
prescribing qualification? What support might be needed to increase your confidence in
making review decision? (professional role/identity, beliefs about capabilities)
• What support is available for you to conduct medication/polypharmacy reviews? What
other support would be desirable? Prompt: additional training, detailed
instructions/guidelines? To which extent do you/can you get support (clinical or otherwise)
from colleagues outside the practices you are affiliated with? (Are you aware of the
polypharmacy guidelines and how do you use them?) (knowledge/skills, memory attention
and decision making, environmental context and resources)
• To which extent is conducting medication/polypharmacy reviews in older people a priority
for you/your colleagues? Prompt: Why/why not? (goals, professional role/identity)
• How satisfied are you with the volume/quality of medication reviews you conduct?
(emotion)
• What are the main benefits of medication/polypharmacy reviews? Prompts: What type of
medication related problems do you encounter /resolve when you conduct medication
reviews? (if any). Do you encounter/address issues with prescribing? Monitoring? Non-
adherence? Which specific drugs are the most problematic or most risky in your opinion?
How thoroughly are reviews usually done? How could the quality of reviews be
ensured/improved?  (goals, beliefs about consequences)
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2 
• How does medication review work fit in with your daily activities/targets? Prompts: How
do you balance this with other work? (behavioural regulation, memory, attention and
decision processes, environmental context and resources)
• How could more medication reviews be encouraged?
Prompts: What do you think is the best way to engage pharmacists to focus on risky
prescribing identified by the informatics tool? What factors that may interfere with
achieving this goal? (Goals, Reinforcement)
• Who else is usually involved in the medication review process? How are the review
decisions made? Prompts: GPs? Nurses? Patients? Carers? How much do they contribute to
the final review decision? Who has the final say? How does the communication flow
between different professionals? How could it be improved? (before, during or after the
review) (social influences, environmental context and resources)
• How well does collaboration between pharmacists and GPs work in your practice? Prompt:
How could a GP/pharmacist collaboration be enhanced, or made more successful? (social
influences, environmental context and resources, reinforcement)
• What consequences would you anticipate from using the informatics tool? Prompt: What
will be the consequences for yourself, other clinical staff or for the patients themselves?
(Beliefs about consequences)
• To which extent do you personally feel prepared to lead on reviewing patients identified
by the informatics tool in the practices you are affiliated with? (intention, optimism)
Closing 
• To support implementation: What should we be aware of, what should we do, what
should we NOT do?  Prompts: What is the most important message that you want us to take
away from this interview? Is there anything else that you would like to add?
• Any questions for us?
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Does the quote refer to barriers or facilitators of the target behaviours A ? [If yes, continue] 
↓ 
Does the quote relate to [Note: it is possible that more than one of the following applies] ... 
… pharmacists’ own cognitive or 
informational resources? 
… pharmacists’ planning of actions or 
reflections on past, current or future 
medication review practice? 
… pharmacists’ reactions, wants 
or needs, impulses, inhibitions or 
reflexive actions [rather than 
reasoned actions]? 
… resources available to 
pharmacists or rules (e.g. health 
board directives) affecting 
pharmacists? 
… interpersonal relationships of 
pharmacists with other practice 
staff or practice culture? 
↓ ↓ ↓ ↓ ↓ 
If yes, choose from the following 
‘capability’ domains: 
If yes, choose from of the following  
‘reflective motivation’ domains: 
If yes, choose from the following 
‘automatic motivation’ domains: 
If yes, code Environmental 
context and resources B [Note: 
Consider coding impact on 
capability, reflective or automatic 
motivation domains] 
If yes, code Social Influences B 
[Note: Consider coding impact 
on capability, reflective or 
automatic motivation domains] 
Knowledge B – Awareness of or 
familiarity with sources of 
information needed to inform 
clinical decision making or 
implementation processes [Note: 
where judgement is involved, 
consider skills or decision making] 
Skills B –Abilities acquired or 
attainable through training or 
experience [rather than just 
ability to access or recall 
information = knowledge] 
Memory, attention and decision 
making processes B – Ability to 
process information and make 
appropriate clinical decisions 
[Note: this includes decisions 
around prioritising patients for 
review] 
Behavioural regulation B - Ability 
to manage, organise or prioritise 
work within practice [Note: 
where reference is made to 
competing demands, also 
consider environmental context 
and resources, social influences) 
Beliefs about capabilities B – 
Confidence in own abilities relating 
to intervention implementation 
[Note: where this relates to the 
pharmacist’s professional role, 
consider professional/social role and 
identity] 
Professional/social role and identity 
B Perceptions of the scope of 
practice, responsibilities and 
boundaries of practice pharmacists  
Beliefs about consequences B - 
Expectations of the impact of the 
intervention on patient outcomes, 
pharmacists’ work, or their work 
environment  
Goals B – Expressions of personal or 
professional aims [Note: Code only if 
this appears to go beyond fulfilment 
of ‘usual’ professional role] 
Optimism B – Expressions of trust in 
the feasibility and benefits of the 
intervention [Note: Only code when 
there is an element of trust; 
otherwise code beliefs about 
consequences] 
Intentions B – Commitment to 
implement the intervention [Note: 
only code if commitment is explicit] 
Emotion B – Pharmacists’ feelings 
towards implementing the 
intervention [Note: Consider 
coding environmental context 
and resources, social influences 
as sources  of emotions] 
Reinforcement B – Stimuli for 
pharmacists to engage (or not) in 
intervention implementation 
[Note: Consider coding 
environmental context and 
resources, social influences as 
sources  of reinforcement] 
A: Targeted behaviours are: pharmacist conducting case note reviews of DTRs identified by the P-DQIP tool and collaborate with GPs in DTR management; B: Where in doubt as to 
whether a quote reflects one domain or another, please code both. Where quotes reflect a cause and effect relationship between two or more domains, please code both the cause 
and the effect.  
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COREQ (COnsolidated criteria for REporting Qualitative research) Checklist 
A checklist of items that should be included in reports of qualitative research. You must report the page number in your manuscript 
where you consider each of the items listed in this checklist. If you have not included this information, either revise your manuscript 
accordingly before submitting or note N/A. 
Topic Item No. Guide Questions/Description Reported on 
Page No. 
Domain 1: Research team 
and reflexivity  
Personal characteristics 
Interviewer/facilitator 1 Which author/s conducted the interview or focus group? 
Credentials 2 What were the researcher’s credentials? E.g. PhD, MD 
Occupation 3 What was their occupation at the time of the study? 
Gender 4 Was the researcher male or female? 
Experience and training 5 What experience or training did the researcher have? 
Relationship with 
participants  
Relationship established 6 Was a relationship established prior to study commencement? 
Participant knowledge of 
the interviewer  
7 What did the participants know about the researcher? e.g. personal 
goals, reasons for doing the research  
Interviewer characteristics 8 What characteristics were reported about the inter viewer/facilitator? 
e.g. Bias, assumptions, reasons and interests in the research topic
Domain 2: Study design 
Theoretical framework 
Methodological orientation 
and Theory  
9 What methodological orientation was stated to underpin the study? e.g. 
grounded theory, discourse analysis, ethnography, phenomenology, 
content analysis  
Participant selection 
Sampling 10 How were participants selected? e.g. purposive, convenience, 
consecutive, snowball  
Method of approach 11 How were participants approached? e.g. face-to-face, telephone, mail, 
email  
Sample size 12 How many participants were in the study? 
Non-participation 13 How many people refused to participate or dropped out? Reasons? 
Setting 
Setting of data collection 14 Where was the data collected? e.g. home, clinic, workplace 
Presence of non-
participants 
15 Was anyone else present besides the participants and researchers? 
Description of sample 16 What are the important characteristics of the sample? e.g. demographic 
data, date  
Data collection 
Interview guide 17 Were questions, prompts, guides provided by the authors? Was it pilot 
tested?  
Repeat interviews 18 Were repeat inter views carried out? If yes, how many? 
Audio/visual recording 19 Did the research use audio or visual recording to collect the data? 
Field notes 20 Were field notes made during and/or after the inter view or focus group? 
Duration 21 What was the duration of the inter views or focus group? 
Data saturation 22 Was data saturation discussed? 
Transcripts returned 23 Were transcripts returned to participants for comment and/or 
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Topic Item No. Guide Questions/Description Reported on 
Page No. 
correction? 
Domain 3: analysis and 
findings  
Data analysis 
Number of data coders 24 How many data coders coded the data? 
Description of the coding 
tree 
25 Did authors provide a description of the coding tree? 
Derivation of themes 26 Were themes identified in advance or derived from the data? 
Software 27 What software, if applicable, was used to manage the data? 
Participant checking 28 Did participants provide feedback on the findings? 
Reporting 
Quotations presented 29 Were participant quotations presented to illustrate the themes/findings? 
Was each quotation identified? e.g. participant number  
Data and findings consistent 30 Was there consistency between the data presented and the findings? 
Clarity of major themes 31 Were major themes clearly presented in the findings? 
Clarity of minor themes 32 Is there a description of diverse cases or discussion of minor themes? 
Developed from: Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist 
for interviews and focus groups. International Journal for Quality in Health Care. 2007. Volume 19, Number 6: pp. 349 – 357 
Once you have completed this checklist, please save a copy and upload it as part of your submission. DO NOT include this 
checklist as part of the main manuscript document. It must be uploaded as a separate file. 
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